Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial

AI Summary

Sichuan Biokin Pharmaceutical's experimental cancer drug iza-bren showed a significant advantage over platinum-based chemotherapy in a phase 3 trial involving 432 patients with advanced lung cancer. The randomized, double-blind study was conducted at 73 hospitals in China, and the findings were presented at the ESMO Congress in Madrid.

An anticancer drug developed by Sichuan Biokin Pharmaceutical took centre stage in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid last week. Researchers said the drug, iza-bren, showed a significant advantage over platinum-based chemotherapy in a phase 3 randomised, double-blind clinical trial conducted at 73 hospitals in China and involving 432 patients with advanced lung cancer. The median progression-free survival (PFS) – the length of...